The world's most advanced malaria vaccine got the nod Friday from European regulators, despite mixed trial results, for eventual use in children in African countries plagued by the killer disease.
Dubbed Mosquirix or RTS,S, the drug received a "positive scientific opinion" from the European Medicines Agency (EMA) following decades of research and millions of dollars of investment.
But it has yet to pass a final World Health Organization (WHO) hurdle, and may not become available before 2017.
Mosquirix is the most clinically-advanced vaccine against the mosquito-borne disease that infects some 200 million people and kills about 600,000 every year, more than 75 percent of them children under five.
In sub-Saharan Africa alone, the plasmodium parasite kills about 1,200 children on average per day, according to the WHO.
The EMA's Committee for Medicinal Products for Human Use had analysed the quality, safety and efficacy of the drug, and its benefit-to-risk ratio, "for use outside the European Union".
Next, the WHO must decide whether to recommend Mosquirix' use in vaccination programmes -- after which it will be up to national regulators to licence the drug.
WHO spokesman Gregory Hartl said the UN's health body should make the decision by November.
Developed by GlaxoSmithKline, Mosquirix is the first malaria vaccine to reach the stage of being assessed by a regulatory agency.
"The EMA assessment is not a recommendation to use this vaccine," Hartl underlined.
The WHO has yet to "look at how the vaccine is produced and if it is produced well enough and under proper manufacturing conditions so that we can have faith in ordering it for the UN system," he told journalists in Geneva.
Mosquirix may become the first licenced vaccine against a parasitic disease, but Hartl underlined: "We understand that 2017 is the earliest that this may occur."
Developed with funding from the Bill & Melinda Gates Foundation, Mosquirix was the first candidate malaria vaccine to reach Phase III clinical testing -- the final stage before market approval.
It is meant to shield children between six weeks and 17 months of age, and also protects against hepatitis B.
In April, the results of a years-long trial with 15,500 children in seven African countries were published in The Lancet medical journal -- announcing mixed success.
'Not the complete answer'
The drug offered only partial protection that waned with time, researchers found, but even so could prevent millions of cases.
The EMA committee concluded that despite the vaccine's limited efficacy, "the benefits of Mosquirix outweigh the risks," said a statement.
The malaria parasite has developed resistance to successive treatments. While there is a limited medicine chest available, insecticide-treated bed nets remain one of the most effective prevention methods.
GSK boss Andrew Witty said Friday that Mosquirix on its own was "not the complete answer".
"Its use alongside those interventions currently available such as bed nets and insecticides would provide a very meaningful contribution to controlling the impact of malaria on children in those African communities that need it the most," he said in a statement.
Added Hartl: "Any financing for this vaccine must not draw resources away from scaling up bed-nets, effective drugs and rapid diagnostic tests for malaria."
GSK said it would provide the drug at a "not-for-profit price".
"Every day, I see first-hand the enormous toll malaria takes on children, families and communities here in Kenya and across Africa," Patricia Njuguna, a principal investigator on the Kenyan leg of the drug trial, said in a statement.
"The prospect of a malaria vaccine coming one step closer to reality is good news."
David Schellenberg, a professor of malaria at the London School of Hygiene & Tropical Medicine, said EMA decision came at a key moment, "when insecticide and drug resistance threaten the cornerstones of malaria prevention and treatment".
"Although RTS,S has only partial efficacy it can clearly contribute to further major gains in malaria control if used judiciously," he said in comments via the Science Media Centre.
AFP
Fri Jul 24 2015
![Malaria vaccine gets regulatory nod Malaria vaccine gets regulatory nod](https://resizer-awani.eco.astro.com.my/tr:w-177,h-100,q-100,f-auto/http://img.astroawani.com/2015-07/71437747508_Malaria.jpg)
This undated photo courtesy of Sanaria, Inc. of Rockville, Maryland, shows Malaria infected mosquitoes ready for dissection in the lab's manufacturing facility during vaccine production.
PAC beri tempoh tiga bulan kepada HRD Corp
Jawatankuasa Kira-kira Wang Negara (PAC) memberi tempoh tiga bulan kepada Perbadanan Pembangunan Sumber Manusia (HRD Corp) untuk mengemukakan laporan tindakan susulan terhadap syor jawatankuasa itu.
Kylian Mbappe tandatangan kontrak dengan Real Madrid
Bintang bola sepak Perancis Kylian Mbappe menandatangani kontrak selama lima tahun dengan kelab Sepanyol Real Madrid pada Selasa.
Pelepasan ketujuh air sisa nuklear Fukushima ke laut selesai
Jepun telah menyelesaikan pusingan ketujuh pelepasan air sisa radioaktif yang dirawat dari loji kuasa nuklear Fukushima Daiichi ke Lautan Pasifik pada Selasa.
Empat termasuk kapten maut dalam pertempuran
Empat anggota tentera India termasuk kapten meninggal dunia akibat kecederaan selepas pertempuuran pada malam isnin di Hutan Desa.
Pakistan sahkan 4 warganya terbunuh di Oman
Pakistan berkata pada Selasa empat warganya terbunuh dalam insiden tembakan pada malam Isnin berhampiran ibu negara Oman, Muscat.
Lima terbunuh, puluhan cedera dalam protes antikuota di Bangladesh
Sekurang-kurangnya empat orang terbunuh dan puluhan lagi cedera dalam pertempuran antara pelajar yang memprotes sistem kuota dalam pekerjaan sektor awam dan polis di pelbagai bahagian Bangladesh pada Selasa.
Kerajaan cadang perkenal pembiayaan swasta
Kerajaan menyasarkan untuk memperkenalkan pembiayaan swasta alternatif bagi memastikan kemampanan kewangan program sektor air, sekali gus mengurangkan kebergantungan pada perbelanjaan kerajaan dan mengukuhkan daya tahan.
Saya tak fitnah Guan Eng, cuma jelaskan siasatan SPRM - Muhyiddin
Presiden Bersatu Tan Sri Muhyiddin Yassin memberitahu Mahkamah Tinggi Kuala Lumpur hari ini bahawa beliau tidak memfitnah Lim Guan Eng berhubung isu pengecualian cukai terhadap Yayasan Albukhary
KPT alu-alukan dapatan, cadangan PAC - Zambry
Ini termasuklah cadangan pelaksanaan Garis Panduan Pelaburan dan Pembiayaan oleh Universiti Awam 2024 kepada anak-anak syarikat di bawah seliaan Kementerian Pendidikan Tinggi (KPT).
Lebih 340,000 syarikat buat transaksi serah simpan maklumat pemunyaan benefisial
Sebanyak 340,637 syarikat telah membuat transaksi serah simpan maklumat pemunyaan benefisial (beneficial ownership) bagi tempoh 1 April hingga 14 Julai lepas.
![COVID-19: Situasi di Eropah stabil namun pandemik belum berakhir - EMA COVID-19: Situasi di Eropah stabil namun pandemik belum berakhir - EMA](https://resizer-awani.eco.astro.com.my/tr:w-177,h-100,q-100,f-auto/https://img.astroawani.com/2022-03/41647045604_COVID.jpg)
COVID-19: Situasi di Eropah stabil namun pandemik belum berakhir - EMA
Semua pihak perlu terus berwaspada dan harus bersedia untuk kemunculan varian baharu dan kemungkinan lonjakan kes COVID-19 terutamanya pada musim sejuk akan datang.
![Ubat COVID-19: EU tandatangan perjanjian dengan GSK Ubat COVID-19: EU tandatangan perjanjian dengan GSK](https://resizer-awani.eco.astro.com.my/tr:w-177,h-100,q-100,f-auto/https://img.astroawani.com/2021-07/41627516739_TBGSK.jpg)
Ubat COVID-19: EU tandatangan perjanjian dengan GSK
Dibangunkan bersama firma Amerika Syarikat Vir Biotechnology, ubat ini boleh digunakan untuk pesakit koronavirus berisiko tinggi dengan gejala ringan, yang tidak memerlukan oksigen.
![Berita antarabangsa pilihan sepanjang hari ini Berita antarabangsa pilihan sepanjang hari ini](https://resizer-awani.eco.astro.com.my/tr:w-177,h-100,q-100,f-auto/https://img.astroawani.com/2021-04/51617709639_BAP.jpg)
Berita antarabangsa pilihan sepanjang hari ini
Antara pelbagai berita luar negara yang disiarkan di Astro AWANI, berikut adalah antara yang paling menjadi tumpuan sepanjang hari ini.
![Campuran vaksin COVID-19: EMA enggan kemuka sebarang saranan Campuran vaksin COVID-19: EMA enggan kemuka sebarang saranan](https://resizer-awani.eco.astro.com.my/tr:w-177,h-100,q-100,f-auto/https://img.astroawani.com/2021-07/61626084581_TBSinovac.jpg)
Campuran vaksin COVID-19: EMA enggan kemuka sebarang saranan
EMA menegaskan, adalah terlalu awal untuk mengesahkan pemberian vaksin dari pengeluar berbeza sebagai selamat.
![COVID-19: EU percepat penilaian vaksin Moderna untuk kanak-kanak COVID-19: EU percepat penilaian vaksin Moderna untuk kanak-kanak](https://resizer-awani.eco.astro.com.my/tr:w-177,h-100,q-100,f-auto/https://img.astroawani.com/2021-04/71618366566_vaccine.jpg)
COVID-19: EU percepat penilaian vaksin Moderna untuk kanak-kanak
EMA akan mempercepatkan penilaian data yang dikemukakan, namun ia menjangkakan kelewatan sekiranya maklumat tambahan diperlukan.
![Vaksin COVID: EU lulus penggunaan Pfizer-BioNTech terhadap remaja Vaksin COVID: EU lulus penggunaan Pfizer-BioNTech terhadap remaja](https://resizer-awani.eco.astro.com.my/tr:w-177,h-100,q-100,f-auto/https://img.astroawani.com/2021-05/71621385693_PFIZER.jpg)
Vaksin COVID: EU lulus penggunaan Pfizer-BioNTech terhadap remaja
Suruhanjaya Eropah meluluskan penggunaan vaksin Pfizer-BioNTech kepada remaja seawal usia 12 tahun.
![Eropah kaji vaksin Pfizer untuk kanak-kanak Eropah kaji vaksin Pfizer untuk kanak-kanak](https://resizer-awani.eco.astro.com.my/tr:w-177,h-100,q-100,f-auto/https://img.astroawani.com/2020-12/41606892895_TBCOVIDVACCINE.jpg)
Eropah kaji vaksin Pfizer untuk kanak-kanak
Pemberian vaksin bagi kumpulan umur ini dianggap langkah kritikal ke arah imuniti berkelompok.
![Vaksin AstraZeneca: WHO sifatkan pengesahan masuk akal, perlu kajian lebih teliti Vaksin AstraZeneca: WHO sifatkan pengesahan masuk akal, perlu kajian lebih teliti](https://resizer-awani.eco.astro.com.my/tr:w-177,h-100,q-100,f-auto/https://img.astroawani.com/2021-03/71616306146_AstraZeneca.jpg)
Vaksin AstraZeneca: WHO sifatkan pengesahan masuk akal, perlu kajian lebih teliti
Ia susulan pengesahan EMA berkenaan kemungkinan hubung kait vaksin AstraZeneca dengan pembekaun darah yang jarang berlaku.
![Vaksin AstraZeneca: Pembekuan darah kesan sampingan sangat jarang berlaku - EMA Vaksin AstraZeneca: Pembekuan darah kesan sampingan sangat jarang berlaku - EMA](https://resizer-awani.eco.astro.com.my/tr:w-177,h-100,q-100,f-auto/https://img.astroawani.com/2021-04/51617846390_ASTRAZENECA.jpg)
Vaksin AstraZeneca: Pembekuan darah kesan sampingan sangat jarang berlaku - EMA
EMA mengesahkan menemui 'kemungkinan' hubung kait antara vaksin AstraZeneca dan masalah pembekuan darah yang jarang berlaku.
![Ini 5 fakta tentang vaksin Oxford-AstraZeneca perlu anda tahu Ini 5 fakta tentang vaksin Oxford-AstraZeneca perlu anda tahu](https://resizer-awani.eco.astro.com.my/tr:w-177,h-100,q-100,f-auto/https://img.astroawani.com/2021-03/51617204242_AstraZenecasvacci.jpg)
Ini 5 fakta tentang vaksin Oxford-AstraZeneca perlu anda tahu
Berikut adalah lima fakta mengenai vaksin ini.